SBio, based in Singapore, is working on a JAK2 Inhibitor for Myelofibrosis patients, SB1518. They have just been granted orphan drug designation from the European Commission. The European Commission is the executive body of the European Union, and has an orphan drug incentive program similar to the U.S. This development potentially expands the market for SBio, which has also received orphan drug designation from the FDA. Phase 2 trials testing safety and efficacy for SB1518 are currently underway in Australia.